Program
opnurasib
Also written as “JDQ443” and “Opnurasib”.
Its studies are mostly in Carcinoma, Non-Small-Cell Lung · Lung Neoplasms · Small Cell Lung Carcinoma, led by Novartis.
Furthest: phase 3, since Nov 11, 20215 company-led studies, 3 open or runningNext primary completion: Jan 25, 2027 (phase 2)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Novartis | 53 open or running | phase 3since Nov 11, 2021 | Jan 5, 2021 | Jan 25, 2027phase 2 · NCT04699188 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jan 5, 2021First study: phase 2 study in Carcinoma, Non-Small-Cell LungFirst studyNCT04699188 · 344 enrolled · United States, Australia, Belgium and more
- Nov 11, 2021Phase 3 study in Carcinoma, Non-Small-Cell LungNCT05132075 · 95 enrolled · United States, Argentina, Australia and more
- Mar 29, 2022Phase 1 study in Small Cell Lung CarcinomaNCT05329623 · 33 enrolled · United States
- Jun 30, 2022Phase 2 study in Lung NeoplasmsNCT05445843 · 95 enrolled · United States, Argentina, Austria and more
- Mar 9, 2026Phase 2 study in Carcinoma, Non-Small-Cell LungNCT07468071 · 25 enrolled · Belgium, Canada, China and more
- Nov 6, 2026Phase 3 study terminatedStudy stoppedNCT05132075 · “Business reasons and not based on any safety concerns.”
Ahead
- Jan 25, 2027Primary completion: phase 2 study in Carcinoma, Non-Small-Cell LungNCT04699188
- Jun 11, 2029Primary completion: phase 2 study in Carcinoma, Non-Small-Cell LungNCT07468071
TargetBeta
KRAS →read by rule
“An inhibitor of the oncogenic KRAS substitution mutation, G12C, ”NCIt, by rule
Other programs on KRAS
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| sotorasibrule | Amgen | phase 3 | 28 |
| adagrasibrule | Bristol-Myers Squibb | phase 3 | 16 |
| olomorasib | Eli Lilly | phase 3 | 16 |
| divarasib | Hoffmann-La Roche | phase 3 | 13 |
| KRAS G12D Inhibitor VS-7375rule | Genfleet Therapeutics (Shanghai) | phase 3 | 12 |
| glecirasibrule | Allist Pharmaceuticals | phase 3 | 12 |
| calderasib | Merck | phase 3 | 12 |
| daraxonrasibrule | Revolution Medicines | phase 3 | 10 |
| garsorasibrule | InventisBio | phase 3 | 8 |
| KRAS G12D Inhibitor HRS-4642 | Jiangsu HengRui Medicine | phase 3 | 7 |
| zoldonrasibrule | Revolution Medicines | phase 3 | 6 |
| HRS-7058 | Jiangsu HengRui Medicine | phase 3 | 6 |
Studies
All 5 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07468071Carcinoma, Non-Small-Cell Lung · Belgium, Canada, China and more | 2 | Active, not recruiting | Jun 11, 2029 | 25 |
| NCT05445843Lung Neoplasms · United States, Argentina, Austria and more | 2 | Active, not recruiting | Nov 4, 2024 | 95 |
| NCT05329623Small Cell Lung Carcinoma · United States | 1 | Completed | Apr 7, 2024 | 33 |
| NCT05132075Carcinoma, Non-Small-Cell Lung · United States, Argentina, Australia and more | 3 | Terminated | Sep 3, 2026 | 95 |
| NCT04699188Carcinoma, Non-Small-Cell Lung · United States, Australia, Belgium and more | 2 | Active, not recruiting | Jan 25, 2027 | 344 |
How it is read
Names in the registry
- “JDQ443”, 4 entries
- “Opnurasib”, 1 entry
Conditions, from the studies’ own filings
- Carcinoma, Non-Small-Cell Lung, 3 studies
- Lung Neoplasms, 1 study
- Small Cell Lung Carcinoma, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.